In a new Westlaw Today article, Thompson Coburn partner Olga Berson discusses opportunities and intellectual property pitfalls for sovereign wealth funds committing capital to U.S. life sciences companies.
“As sovereign wealth funds (SWFs) from Saudi Arabia, Qatar, the UAE, and other Middle Eastern economies expand into U.S. innovation sectors, life sciences have become a prime target,” Olga wrote. “Biotech valuations and IPOs have cooled from their 2021 peak, creating attractive entry points for long-term capital. But alongside the opportunity lies a critical risk: intellectual property, often the most valuable asset in biotech and pharma, where hidden weaknesses can quietly erode investment value.”
She outlines five core IP challenges, including weak patent claims and unclear ownership, plus additional risks investors should keep in mind.
Read the full article here.
